Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer

被引：29

作者：

Di Fiore, F. ^{[1
,2
]}

Charbonnier, F. ^{[1
]}

Lefebure, B. ^{[1
,3
]}

Laurent, M. ^{[4
]}

Le Pessot, F. ^{[1
,4
]}

Michel, P. ^{[1
,2
]}

Frebourg, T. ^{[1
]}

机构：

[1] INSERM, U614, Fac Med, Inst Biomed Res, Rouen, France

[2] Univ Hosp, Digest Oncol Unit, Dept Hepatogastroenterol, Rouen, France

[3] Univ Hosp, Dept Surg, Rouen, France

[4] Univ Hosp, Dept Pathol, Rouen, France

来源：

BRITISH JOURNAL OF CANCER | 2008年 / 99卷 / 03期

关键词：

D O I：

10.1038/sj.bjc.6604451

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：551 / 552

页数：2

共 9 条

[1] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[2] Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies [J].

Benvenuti, Silvia ;

Sartore-Bianchi, Andrea ;

Di Nicolantonio, Federica ;

Zanon, Carlo ;

Moroni, Mauro ;

Veronese, Silvio ;

Siena, Salvatore ;

Bardelli, Alberto .

CANCER RESEARCH, 2007, 67 (06) :2643-2648

[3] KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab [J].

De Roock, W. ;

Piessevaux, H. ;

De Schutter, J. ;

Janssens, M. ;

De Hertogh, G. ;

Personeni, N. ;

Biesmans, B. ;

Van Laethem, J. -L. ;

Peeters, M. ;

Humblet, Y. ;

Van Cutsem, E. ;

Tejpar, S. .

ANNALS OF ONCOLOGY, 2008, 19 (03) :508-515

[4] Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy [J].

Di Fiore, F. ;

Blanchard, F. ;

Charbonnier, F. ;

Le Pessot, F. ;

Lamy, A. ;

Galais, M. P. ;

Bastit, L. ;

Killian, A. ;

Sesboue, R. ;

Tuech, J. J. ;

Queuniet, A. M. ;

Paillot, B. ;

Sabourin, J. C. ;

Michot, F. ;

Michel, P. ;

Frebourg, T. .

BRITISH JOURNAL OF CANCER, 2007, 96 (08) :1166-1169

[5] PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients [J].

Frattini, M. ;

Saletti, P. ;

Romagnani, E. ;

Martin, V. ;

Molinari, F. ;

Ghisletta, M. ;

Camponovo, A. ;

Etienne, L. L. ;

Cavalli, F. ;

Mazzucchelli, L. .

BRITISH JOURNAL OF CANCER, 2007, 97 (08) :1139-1145

[6] Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab [J].

Khambata-Ford, Shirin ;

Garrett, Christopher R. ;

Meropol, Neal J. ;

Basik, Mark ;

Harbison, Christopher T. ;

Wu, Shujian ;

Wong, Tai W. ;

Huang, Xin ;

Takimoto, Chris H. ;

Godwin, Andrew K. ;

Tan, Benjamin R. ;

Krishnamurthi, Smitha S. ;

Burris, Howard A., III ;

Poplin, Elizabeth A. ;

Hidalgo, Manuel ;

Baselga, Jose ;

Clark, Edwin A. ;

Mauro, David J. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (22) :3230-3237

[7] KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer [J].

Lièvre, A ;

Bachet, JB ;

Le Corre, D ;

Boige, V ;

Landi, B ;

Emile, JF ;

Côté, JF ;

Tomasic, G ;

Penna, C ;

Ducreux, M ;

Rougier, P ;

Penault-Llorca, F ;

Laurent-Puig, P .

CANCER RESEARCH, 2006, 66 (08) :3992-3995

[8] KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab [J].

Lievre, Astrid ;

Bachet, Jean-Baptiste ;

Boige, Valerie ;

Cayre, Anne ;

Le Corre, Delphine ;

Buc, Emmanuel ;

Ychou, Marc ;

Bouche, Olivier ;

Landi, Bruno ;

Louvet, Christophe ;

Andre, Thierry ;

Bibeau, Frederic ;

Diebold, Marie-Daniele ;

Rougier, Philippe ;

Ducreux, Michel ;

Tomasic, Gorana ;

Emile, Jean-Francois ;

Penault-Llorca, Frederique ;

Laurent-Puig, Pierre .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (03) :374-379

[9] Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers [J].

Park, Hye-Won ;

Kang, Hio Chung ;

Kim, Il-Jin ;

Jang, Sang-Geun ;

Kim, Kun ;

Yoon, Hyun-Ju ;

Jeong, Seung-Yong ;

Park, Jae-Gahb .

INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (01) :7-12

← 1 →